DAM
ACHN

Doheny Asset Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Doheny Asset Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-22,000
Closed -$59K – 96
2019
Q2 		$59K Hold
22,000
– – 0.05% 91
2019
Q1 		$65K Hold
22,000
– – 0.06% 94
2018
Q4 		$35K Hold
22,000
– – 0.03% 89
2018
Q3 		$81K Hold
22,000
– – 0.04% 100
2018
Q2 		$62K Sell
22,000
-17,000
-44% -$57.9K 0.03% 100
2018
Q1 		$145K Hold
39,000
– – 0.08% 102
2017
Q4 		$112K Hold
39,000
– – 0.05% 106
2017
Q3 		$175K Hold
39,000
– – 0.08% 107
2017
Q2 		$179K Sell
39,000
-1,000
-3% -$4.02K 0.08% 105
2017
Q1 		$168K Hold
40,000
– – 0.08% 112
2016
Q4 		$165K Sell
40,000
-44,850
-53% -$238K 0.08% 106
2016
Q3 		$687K Sell
84,850
-21,000
-20% -$179K 0.35% 64
2016
Q2 		$826K Sell
105,850
-5,800
-5% -$49.8K 0.41% 56
2016
Q1 		$862K Sell
111,650
-348,900
-76% -$2.56M 0.44% 55
2015
Q4 		$4.97M Sell
460,550
-49,575
-10% -$451K 2.43% 10
2015
Q3 		$3.52M Sell
510,125
-42,875
-8% -$349K 1.83% 19
2015
Q2 		$4.9M Buy
553,000
+51,050
+10% +$483K 2.19% 13
2015
Q1 		$4.95M Sell
501,950
-15,500
-3% -$194K 2.29% 12
2014
Q4 		$6.34M Sell
517,450
-24,875
-5% -$304K 3.03% 7
2014
Q3 		$5.41M Sell
542,325
-183,900
-25% -$1.71M 2.71% 9
2014
Q2 		$5.5M Sell
726,225
-396,100
-35% -$1.58M 2.6% 9
2014
Q1 		$3.69M Buy
1,122,325
+144,300
+15% +$505K 1.9% 16
2013
Q4 		$3.25M Buy
978,025
+910,375
+1,346% +$2.64M 1.71% 21
2013
Q3 		$204K Buy
67,650
+20,645
+44% +$142K 0.11% 92
2013
Q2 		$385K Buy
+47,005
New +$359K 0.22% 83

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Doheny Asset Management's ACHN Position: Q3 2019 in Review

Doheny Asset Management sold out of Achillion Pharmaceuticals (ACHN) in Q3 2019, closing a stake of 22,000 shares — an estimated $59K sold.

Doheny Asset Management first reported a position in ACHN in Q2 2013 and held it in 25 quarters. The position peaked at $6.34M in Q4 2014. 122 funds tracked by Wall St. Rank hold ACHN as of Q3 2019.

  • Doheny Asset Management reported no remaining Achillion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Doheny Asset Management sold 22,000 Achillion Pharmaceuticals shares in Q3 2019, an estimated $59K.
  • Doheny Asset Management first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 25 quarters.
  • Doheny Asset Management's Achillion Pharmaceuticals position peaked at $6.34M in Q4 2014.
  • 122 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2019.

Based on Doheny Asset Management's 13F filing for Q3 2019, filed 15 Nov 2019.